Clinical Trial

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2026 (before its estimated March 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-08; most recent amendment 2026-01-27.
Status change: Withheld → Recruiting 2025-09-30
Trial Details
NCT Number NCT06919081
Lead Sponsor University of Illinois at Chicago
Collaborators: National Eye Institute (NEI), National Institutes of Health (NIH)
Conditions Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
Enrollment 24 participants
Start Date 2025-08-01
Primary Completion 2026-03-15 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-29